

# Letters

## RESEARCH LETTER

### Gastrointestinal Complications in Critically Ill Patients With and Without COVID-19

Coronavirus disease 2019 (COVID-19) appears to have significant extrapulmonary complications affecting multiple organ systems.<sup>1-3</sup> Critically ill patients with COVID-19 often develop gastrointestinal complications during their hospital stay, including bowel ischemia, transaminitis, gastrointestinal bleeding, pancreatitis, Ogilvie syndrome, and severe ileus.<sup>3</sup> Whether the high incidence of gastrointestinal complications is a manifestation of critical illness in general or is specific to COVID-19 remains unclear. We compared the

incidence of gastrointestinal complications of critically ill patients with COVID-19-induced acute respiratory distress syndrome (ARDS) vs comparably ill patients with non-COVID-19 ARDS using propensity score analysis.

**Methods** | All patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on reverse transcriptase-polymerase chain reaction who were intubated and admitted to 1 of 13 (preexistent and surge) intensive care units (ICUs) of the Massachusetts General Hospital between March 13, 2020, and May 7, 2020, were included, then matched to a cohort of patients admitted between 2018 and 2019 and meeting the Berlin criteria for ARDS.<sup>4</sup> No changes

Table. Baseline Population Characteristics and Outcomes

Characteristic/outcome	No. (%)		P value
	Non-COVID-19 ARDS	COVID-19 ARDS	
<b>Prematching characteristics</b>			
No. of patients	244	242	
Age, median (IQR), y	62 (53-73.5)	60.5 (48-71)	.09
BMI, median (IQR) <sup>a</sup>	27.5 (23-32)	30 (27-35)	<.001
<b>Sex</b>			
Female	110 (45.1)	81 (33.5)	.009
Male	134 (54.9)	161 (66.5)	
Smoking	164 (67.2)	68 (28.1)	<.001
SOFA score, median (IQR)	7 (5-9)	6 (4-8)	<.001
<b>Comorbidities</b>			
Hypertension	144 (59.0)	128 (52.9)	.17
Chronic lung disease <sup>b</sup>	104 (42.6)	51 (21.1)	<.001
Diabetes	64 (26.2)	109 (45.0)	<.001
Congestive heart failure	56 (23.0)	19 (7.9)	<.001
Coronary artery disease	45 (18.4)	25 (10.3)	.01
Chronic kidney disease	42 (17.2)	38 (15.7)	.65
<b>Postmatching characteristics</b>			
No. of patients	92	92	
Age, median (IQR), y	64.5 (51.5-75.5)	62 (48.5-71.5)	.24
BMI, median (IQR) <sup>a</sup>	28 (25-33.5)	29 (25-32.5)	.55
<b>Sex</b>			
Female	40 (43)	38 (41)	.77
Male	52 (57)	54 (59)	
Smoking	39 (42)	36 (39)	.65
SOFA score, median (IQR)	7 (4-8.5)	7 (5-9)	.86
<b>Comorbidities</b>			
Hypertension	50 (54)	51 (55)	.88
Diabetes	35 (38)	34 (37)	.88
Chronic lung disease	29 (32)	27 (29)	.75
Chronic kidney disease	17 (18)	18 (20)	.85
Coronary artery disease	14 (15)	12 (13)	.67
Congestive heart failure	13 (14)	15 (16)	.68

(continued)

**Table. Baseline Population Characteristics and Outcomes (continued)**

Characteristic/outcome	No. (%)		P value
	Non-COVID-19 ARDS	COVID-19 ARDS	
<b>Outcomes</b>			
No. of patients	92	92	
PaO <sub>2</sub> :FiO <sub>2</sub> ratio <sup>c</sup>	168 (136-228)	191.5 (145.5-331)	.05
Any gastrointestinal complication	34 (37)	68 (74)	<.001
Transaminitis	25 (27)	51 (55)	<.001
Ileus	20 (22)	44 (48)	<.001
Ogilvie syndrome	1 (1)	2 (2)	.56
Mesenteric ischemia	0	4 (4)	.04
30-d Mortality	21 (23)	23 (25)	.73
Hospital LOS, median (IQR)	14 (9-24)	24 (13-36)	<.001
ICU LOS, median (IQR)	8.5 (4.5-15)	17 (8-25)	<.001
Days on opioid drip, median (IQR)	9 (4-15)	1 (0-4.5)	<.001
Days on ventilation, median (IQR)	6 (3-11)	13.5 (8.5-22.5)	<.001
Tracheostomy	11 (12)	28 (30)	.002
Emergency department readmission	10 (11)	10 (11)	.98
<b>Other complications</b>			
Venous thromboembolism	6 (7)	9 (10)	.42
Acute kidney injury	63 (68)	72 (78)	.13
Dialysis <sup>d</sup>	14 (22)	21 (29)	.36

Abbreviations: ARDS, acute respiratory distress syndrome; BMI, body mass index; COVID-19, coronavirus disease 2019; FiO<sub>2</sub>, fraction of inspired oxygen; ICU, intensive care unit; IQR, interquartile range; LOS, length of stay; PaO<sub>2</sub>, partial pressure of arterial oxygen; SOFA, Sequential Organ Failure Assessment.


<sup>a</sup> Calculated as weight in kilograms divided by height in meters squared.

<sup>b</sup> Includes asthma, chronic obstructive pulmonary disease, and interstitial lung disease.

<sup>c</sup> PaO<sub>2</sub>:FiO<sub>2</sub> ratio on admission to the ICU.

<sup>d</sup> Percentage is of patients with acute kidney injury.

**Figure. Kaplan-Meier Curves of Gastrointestinal Complications in Patients With Acute Respiratory Distress Syndrome (ARDS) With and Without Coronavirus Disease 19 (COVID-19)**



The 2 curves initially look similar but start separating around day 3 of the intensive care unit stay.

occurred in the ICU staffing models or protocols of care of ARDS during the study period. Propensity score matching was performed adjusting for demographics (eg, age, sex, body mass index, smoking status), comorbidities (eg, chronic lung/kidney disease, congestive heart failure, coronary artery disease, hypertension, diabetes), and severity of illness on ICU admission (Sequential Organ Failure Assessment score). We examined in both groups the following gastrointestinal complications: transaminitis, ileus, Ogilvie syndrome, and mesenteric ischemia.

Wilcoxon rank sum, Pearson  $\chi^2$ , and Fisher exact tests were used, as appropriate. To determine whether differences in the duration of illness between groups might contribute, inci-

dence rate ratios and Kaplan-Meier curves looking at time to development of the complication from hospital admission were calculated. All tests were 2-tailed; statistical significance was defined as  $P < .05$ . Statistical analyses were performed on Stata version 15.0 (StataCorp LP). The Mass General Brigham Institutional Review Board ruled this study exempt including a waiver of informed consent.

**Results** | A total of 486 patients with ARDS met eligibility criteria, of which 244 had non-COVID-19 ARDS and 242 had COVID-19 ARDS. This report includes data from 141 patients with COVID-19 (58%) whose overall gastrointestinal complications have been previously described.<sup>3</sup> The median

age of patients was 60.5 years (interquartile range, 48-71) and 62 years (interquartile range, 53-73.5) for patients with and without COVID-19, respectively, and the percentage of males was 66.5% and 54.9%, respectively.

Ninety-two patients with COVID-19 and ARDS were propensity score matched to 92 patients with non-COVID-19 ARDS (Table). The etiologies for ARDS among the non-COVID-19-matched cohort were bacterial pneumonia (60%), aspiration (27%), influenza (7%), respiratory syncytial virus infection (2%), and *Pneumocystis jirovecii* pneumonia (2%). Patients with COVID-19 were more likely to develop gastrointestinal complications compared with those without COVID-19 (74% vs 37%;  $P < .001$ ; incidence rate ratio, 2.33 [95% CI, 1.52-3.63]). The difference in incidence was more evident after the third day of critical illness (Figure). Specifically, patients with COVID-19 developed more transaminitis (55% vs 27%;  $P < .001$ ), severe ileus (48% vs 22%;  $P < .001$ ), and bowel ischemia (4% vs 0%;  $P = .04$ ). Three of the 4 patients with COVID-19 and bowel ischemia were taken to the operating room and had intraoperative findings consistent with COVID-19 bowel as previously described in different patients.<sup>3</sup> Pathology findings demonstrated fibrin thrombi in the microvasculature underlying areas of necrosis.

**Discussion** | This study found a higher rate of gastrointestinal complications, including mesenteric ischemia, in critically ill patients with COVID-19 compared with propensity score-matched patients without COVID-19, suggesting a distinct phenotype for COVID-19 compared with conventional ARDS. High expression of angiotensin-converting enzyme 2 receptors along the epithelial lining of the gut that act as host-cell receptors for SARS-CoV-2 could explain involvement of abdominal organs.<sup>5</sup> Higher opioid requirements and COVID-19-induced coagulopathy may also explain the disproportionately high rate of ileus and ischemic bowel disease.<sup>2</sup> Differences in duration of illness did not seem to explain the differences in gastrointestinal complications. Limitations of this study include the single center and the unavailability of inflammatory markers to use for matching. Further translational studies are warranted to examine the pathophysiology of these findings.

**Mohamad El Moheb, MD**  
**Leon Naar, MD**  
**Mathias A. Christensen, BSc**  
**Carolijn Kapoen, BSc**  
**Lydia R. Maurer, MD**  
**Maha Farhat, MD, MSc**  
**Haytham M. A. Kaafarani, MD, MPH**

**Author Affiliations:** Division of Trauma, Emergency Surgery, and Surgical Critical Care, Massachusetts General Hospital, Boston (El Moheb, Naar, Christensen, Kapoen, Maurer, Kaafarani); Division of Pulmonary and Critical Care, Massachusetts General Hospital, Boston (Farhat).

**Corresponding Author:** Haytham M. A. Kaafarani, MD, MPH, Harvard Medical School, Division of Trauma, Emergency Surgery, and Surgical Critical Care, 165 Cambridge St, Ste 810, Boston, MA 02114 (hkaafarani@mgh.harvard.edu).

**Accepted for Publication:** September 14, 2020.

**Published Online:** September 24, 2020. doi:10.1001/jama.2020.19400

**Author Contributions:** Dr Kaafarani had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

*Concept and design:* El Moheb, Naar, Christensen, Maurer, Kaafarani.

*Acquisition, analysis, or interpretation of data:* All authors.

*Drafting of the manuscript:* El Moheb, Farhat, Kaafarani.

*Critical revision of the manuscript for important intellectual content:* All authors.

*Statistical analysis:* El Moheb, Naar, Christensen, Maurer, Farhat, Kaafarani.

*Administrative, technical, or material support:* Kaafarani.

*Supervision:* Maurer, Farhat, Kaafarani.

**Conflict of Interest Disclosures:** None reported.

**Additional Contributions:** We thank George Velmahos, MD, PhD, Division of Trauma, Emergency Surgery, and Surgical Critical Care, Massachusetts General Hospital, Boston, for his clinical expertise and advice. Dr Velmahos was not compensated for his contributions.

- Hirsch JS, Ng JH, Ross DW, et al; Northwell COVID-19 Research Consortium; Northwell Nephrology COVID-19 Research Consortium. Acute kidney injury in patients hospitalized with COVID-19. *Kidney Int*. 2020;98(1):209-218. doi:10.1016/j.kint.2020.05.006
- Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. *Lancet Haematol*. 2020;7(6):e438-e440. doi:10.1016/S2352-3026(20)30145-9
- Kaafarani HMA, El Moheb M, Hwabejire JO, et al. Gastrointestinal complications in critically ill patients with COVID-19. *Ann Surg*. 2020;272(2):e61-e62. doi:10.1097/SLA.0000000000004004
- Ranieri VM, Rubenfeld GD, Thompson BT, et al; ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin Definition. *Jama*. 2012;307(23):2526-2533.
- Qi F, Qian S, Zhang S, Zhang Z. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. *Biochem Biophys Res Commun*. 2020;526(1):135-140. doi:10.1016/j.bbrc.2020.03.044